{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T13:36:39Z","timestamp":1794231399244,"version":"4.9.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:00:00Z","timestamp":1794182400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-May23\/100001"],"award-info":[{"award-number":["DRCRPG-May23\/100001"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>CD163+ tumor-associated macrophages (TAM) are associated with poor response to immunochemotherapy in patients with diffuse large B-cell lymphoma and comprise a significant proportion of the tumor microenvironment (TME). Targeting these TAMs to reverse immunosuppression is an attractive approach for improving treatment response rates. A change in microRNA (miRNA) expression has the potential to modify hundreds of genes by interacting with multiple messenger RNA (mRNA) targets, thereby altering the wider cellular transcriptional profile. The manipulation of miRNAs that control macrophage behavior may switch the global transcriptomic profiles of immunosuppressive macrophages to more activated, antitumor states, resulting in the reversal of immune resistance and enhancement of monoclonal antibody (mAb) therapy. Our studies show a significant upregulation of miR-142-5p in immunosuppressive macrophages stimulated with IL4\/IL13 compared with lipopolysaccharide (LPS)\/IFN\u03b3-stimulated macrophages and nonpolarized controls. This upregulation of miR-142-5p in macrophages stimulated with immunoinhibitory cytokines IL10 and TGF\u03b2 was also demonstrated. Inhibition of miR-142-5p expression in IL4\/IL13-stimulated macrophages led to a significant increase in Fc\u03b3RIIIA, CD40, and CD47 expression with enhanced phagocytosis of chronic lymphocytic leukemia (CLL) cells opsonized with rituximab when compared with nontransfected controls. Expression of miR-142-5p in diagnostic samples of patients with diffuse large B-cell lymphoma (DLBCL) was assessed using miRScope assays. These were combined with immunohistochemistry (IHC) staining of CD206 to identify immunosuppressive macrophages. Combination of high miR-142-5p and CD206 expression correlated with a reduction in progression-free survival (PFS) following standard rituximab containing chemotherapy regimens in 38 patients. Together, these studies indicate the potential of targeting miRNA to repolarize macrophages and improve treatment success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The manipulation of macrophage polarization within the TME has the potential to enhance immunotherapies used across many different cancer types. The use of miRNA inhibitors to target the immune system in a cell-specific way using antibody oligonucleotide conjugates has the potential to reduce toxicity historically associated with miRNA therapeutics and change the phenotype of cells at the transcriptomic level.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0485","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:40:35Z","timestamp":1792014035000},"page":"2631-2643","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MicroRNA Expression in Macrophages Regulates Antibody-Dependent Effector Function and B-cell Lymphoma Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-0686","authenticated-orcid":false,"given":"Jemma","family":"Longley","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-6593","authenticated-orcid":false,"given":"Lekh N.","family":"Dahal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xs57h96","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Liverpool 2 Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology (ISMIB), , Liverpool, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-0708","authenticated-orcid":false,"given":"Russell B.","family":"Foxall","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-0527","authenticated-orcid":false,"given":"Stephen","family":"Thirdborough","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-363X","authenticated-orcid":false,"given":"Margaret","family":"Ashton-Key","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."},{"name":"3Department of Cellular Pathology, University Hospital Southampton, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-5933","authenticated-orcid":false,"given":"Matthew J.","family":"Carter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-1263","authenticated-orcid":false,"given":"Rosanna C.","family":"Smith","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-9273","authenticated-orcid":false,"given":"Robert","family":"Kemp","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 4 Clinical Trials Unit, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-4974","authenticated-orcid":false,"given":"Peter W.M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"5Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6938","authenticated-orcid":false,"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[{"name":"5Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-3342","authenticated-orcid":false,"given":"Stephen A.","family":"Beers","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."},{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 6 Institute for Life Sciences, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 1 Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, Southampton General Hospital, , Southampton, United Kingdom."},{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 6 Institute for Life Sciences, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,11,9]]},"reference":[{"key":"2026110908184863300_bib1","doi-asserted-by":"publisher","first-page":"e000778","DOI":"10.1136\/jitc-2020-000778","article-title":"M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer","volume":"8","author":"Garrido-Martin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026110908184863300_bib2","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1038\/s41598-022-11503-2","article-title":"Role of CD68 in tumor immunity and prognosis prediction in pan-cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"2026110908184863300_bib3","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2026110908184863300_bib4","first-page":"97","article-title":"Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma","volume":"10","author":"Cencini","year":"2020","journal-title":"Am J Blood Res"},{"key":"2026110908184863300_bib5","doi-asserted-by":"publisher","first-page":"1000003","DOI":"10.13188\/2325-4653.1000003","article-title":"Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics","volume":"1","author":"Azad","year":"2014","journal-title":"J Cytol Mol Biol"},{"key":"2026110908184863300_bib6","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","article-title":"Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"2026110908184863300_bib7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fimmu.2017.00086","article-title":"Human tumor-infiltrating myeloid cells: phenotypic and functional diversity","volume":"8","author":"Elliott","year":"2017","journal-title":"Front Immunol"},{"key":"2026110908184863300_bib8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","article-title":"Origin and functions of tissue macrophages","volume":"41","author":"Epelman","year":"2014","journal-title":"Immunity"},{"key":"2026110908184863300_bib9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ni.2705","article-title":"Tissue-resident macrophages","volume":"14","author":"Davies","year":"2013","journal-title":"Nat Immunol"},{"key":"2026110908184863300_bib10","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1158\/0008-5472.CAN-16-2784","article-title":"STING activation reverses lymphoma-mediated resistance to antibody immunotherapy","volume":"77","author":"Dahal","year":"2017","journal-title":"Cancer Res"},{"key":"2026110908184863300_bib11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front Immunol"},{"key":"2026110908184863300_bib12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026110908184863300_bib13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","article-title":"Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies","volume":"125","author":"Tipton","year":"2015","journal-title":"Blood"},{"key":"2026110908184863300_bib14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12033-008-9043-x","article-title":"Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic stem cells","volume":"40","author":"Zhao","year":"2008","journal-title":"Mol Biotechnol"},{"key":"2026110908184863300_bib15","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.4049\/jimmunol.1402988","article-title":"Development and characterization of monoclonal antibodies specific for mouse and human Fc\u03b3 receptors","volume":"195","author":"Tutt","year":"2015","journal-title":"J Immunol"},{"key":"2026110908184863300_bib16","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026110908184863300_bib17","doi-asserted-by":"publisher","first-page":"e05005","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"eLife"},{"key":"2026110908184863300_bib18","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141","article-title":"miRBase: from microRNA sequences to function","volume":"47","author":"Kozomara","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026110908184863300_bib19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/imcb.12369","article-title":"miR-142-5p and miR-130a-3p regulate pulmonary macrophage polarization and asthma airway remodeling","volume":"98","author":"Shi","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"2026110908184863300_bib20","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1038\/ncomms9523","article-title":"miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program","volume":"6","author":"Su","year":"2015","journal-title":"Nat Commun"},{"key":"2026110908184863300_bib21","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.3892\/mmr.2015.3191","article-title":"Upregulation of miR-142-5p in atherosclerotic plaques and regulation of oxidized low-density lipoprotein-induced apoptosis in macrophages","volume":"11","author":"Xu","year":"2015","journal-title":"Mol Med Rep"},{"key":"2026110908184863300_bib22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/ijms19061801","article-title":"Role of human macrophage polarization in inflammation during infectious diseases","volume":"19","author":"Atri","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026110908184863300_bib23","doi-asserted-by":"publisher","first-page":"15035","DOI":"10.18632\/oncotarget.3729","article-title":"MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K\/AKT pathway in diffuse large B-cell lymphoma","volume":"6","author":"Go","year":"2015","journal-title":"Oncotarget"},{"key":"2026110908184863300_bib24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.gene.2017.11.022","article-title":"Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions","volume":"642","author":"Meng","year":"2018","journal-title":"Gene"},{"key":"2026110908184863300_bib25","doi-asserted-by":"publisher","first-page":"12159","DOI":"10.1038\/s41598-023-39271-7","article-title":"microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma","volume":"13","author":"Larrabeiti-Etxebarria","year":"2023","journal-title":"Sci Rep"},{"key":"2026110908184863300_bib26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human Fc\u03b3RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"key":"2026110908184863300_bib27","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"key":"2026110908184863300_bib28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"2026110908184863300_bib29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2020.03.009","article-title":"Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma","volume":"20","author":"Cheson","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026110908184863300_bib30","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"key":"2026110908184863300_bib31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026110908184863300_bib32","first-page":"148","article-title":"Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"key":"2026110908184863300_bib33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccell.2017.11.001","article-title":"Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment","volume":"32","author":"Turaj","year":"2017","journal-title":"Cancer Cell"},{"key":"2026110908184863300_bib34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/CM9.0000000000002919","article-title":"Immune cells in the B-cell lymphoma microenvironment: from basic research to clinical applications","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2026110908184863300_bib35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ncrna.2023.05.004","article-title":"Emerging functions and clinical applications of exosomal microRNAs in diseases","volume":"8","author":"Ghafouri-Fard","year":"2023","journal-title":"Noncoding RNA Res"},{"key":"2026110908184863300_bib36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12094-024-03590-6","article-title":"Exosomal microRNAs: impact on cancer detection, treatment, and monitoring","volume":"27","author":"Kumar","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"2026110908184863300_bib37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"2026110908184863300_bib38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3389\/fimmu.2018.00936","article-title":"The function of microRNAs in B-cell development, lymphoma, and their potential in clinical practice","volume":"9","author":"Zheng","year":"2018","journal-title":"Front Immunol"},{"key":"2026110908184863300_bib39","doi-asserted-by":"publisher","first-page":"49143","DOI":"10.18632\/oncotarget.9237","article-title":"Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"2026110908184863300_bib40","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"issue":"suppl 2","key":"2026110908184863300_bib41","doi-asserted-by":"publisher","first-page":"ii16","DOI":"10.1093\/annonc\/mdv090.2","article-title":"P1.02 * MesomiR 1: a phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC)","volume":"26","author":"van Zandwijk","year":"2015","journal-title":"Ann Oncol"},{"key":"2026110908184863300_bib42","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0485\/3839464\/crc-25-0485.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/11\/2631\/3847161\/crc-25-0485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/11\/2631\/3847161\/crc-25-0485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T13:18:57Z","timestamp":1794230337000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/11\/2631\/789878\/MicroRNA-Expression-in-Macrophages-Regulates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0485","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34957970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957949","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957967","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957955","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957958","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34957931","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8827247","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}